Clinical Trials Logo

Atrial Fibrillation clinical trials

View clinical trials related to Atrial Fibrillation.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06283654 Completed - Atrial Fibrillation Clinical Trials

Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation

relievED
Start date: September 30, 2018
Phase:
Study type: Observational

In our study, we explored a new approach to manage atrial fibrillation, a disease that affects millions worldwide. Our goal was to see if using a simple handheld ECG device for monitoring heart rhythm could help patients avoid unnecessary visits to the emergency department (ED) after undergoing a common procedure known as pulmonary vein isolation (PVI). This procedure is often used to treat AF, but following it patients frequently visit the ED due to concerns about their heart rhythm, which can strain healthcare resources. We provided a group of patients with a 1-lead ECG device , which allows users to check their heart rhythm at any time. We compared the ED utilization over a year with that of patients who received standard care after PVI. Our hope was that by using the 1-lead ECG device, patients could better manage their condition from home and only seek medical help when truly necessary.

NCT ID: NCT06260670 Completed - Clinical trials for Persistent Atrial Fibrillation

FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation

FLOW EVAL-AF
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

FLOW EVAL-AF is a prospective, observational, single center pilot trial. The FLOW EVAL-AF trial is designed to identify driver sources in patients with persistent or longstanding persistent AF using EGF mapping and describe the activation patterns observed from concomitant high density mapping of those regions.

NCT ID: NCT06256965 Completed - Heart Failure Clinical Trials

Cardiopulmonary Bypass and Ventricular Remodeling

CBP-VR
Start date: October 4, 2021
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is determine if reduced ventricular ejection fraction is a factor that determines a pro-oxidant imbalance in patients subjected to cardiac surgery with cardiopulmonary bypass. The main questions are: - 1. Preoperative reduced left ventricular function determines higher blood and atrial tissue oxidative stress in patients subjected to cardiopulmonary bypass - 2. Oxidative stress markers in atrial tissue of cardiac surgical patients with develop atrial fibrillation The main tasks participants will be asked to do is register the symptoms of arrhythmia and heart failure. Also, obtain a electrocardiographic register if any present palpitations or chest pain with clinical significance This study not present a comparison group.

NCT ID: NCT06233721 Completed - Atrial Fibrillation Clinical Trials

The Effect Of Face-To-Face and Online-Education Provided To İndividuals With Atrial Fibrillation On Medication Adherence and Satisfaction

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

This randomized controlled study was conducted to investigate the effects of face-to-face Education and tele-education given to individuals with atrial fibrillation taking oral Anticoagulants on their medication compliance and satisfaction levels. The study sample comprised 150 individuals. Of them, 50 were assigned to the control Group, 50 in the experimental group 1, and 50 for the experimental group 2. Data were collected by the Descriptive Information Form, Medication Compliance Notification Scale and Duke Anticoagulant Satisfaction Scale. The Intervention Group 1 Was given face-to-face education. The Intervention Group 2 was given tele-education. The control group underwent no intervention.

NCT ID: NCT06174129 Completed - Atrial Fibrillation Clinical Trials

Prevalence and Factors Associated With Atrial Fibrillation in Patients With Type 2 Diabetes

Start date: June 1, 2022
Phase:
Study type: Observational

This case-control study was conducted at Burapha University Hospital. The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.

NCT ID: NCT06169332 Completed - Atrial Fibrillation Clinical Trials

Multidetector CT Left Appendage Atrial Thrombosis Exclusion in Patients With Atrial Fibrillation

Start date: December 13, 2010
Phase:
Study type: Observational

The aim of the LATE (multidetector CT Lefi Appendage atrial Thrombosis Exclusion in patients with atrial fibrillation) study is to evaluate the diagnostic accuracy of cardiac Computed Tomography (TC) with 64 detectors and double acquisition phase in candidate patients ablation of atrial fibrillation (AF) with the Navx (or Carto) technique, using trans-esophageal ultrasound (TEE) as the standard reference. This study is based on the use of an experimental protocol in cardiac TC which involves, in addition to the acquisition of an early arterial phase (standard protocol routinely performed in all patients), the execution of a possible late phase at a very low dose of radiation (experimental protocol) aimed at increasing the accuracy of the method in the diagnosis in patients with AF. The LATE study aims to demonstrate the high diagnostic accuracy of dual acquisition phase cardiac TC in the diagnosis of intraauricular thrombosis by comparing it with reference standard; in light of this result, cardiac TC could constitute a single non-invasive diagnostic tool in the future for the global evaluation of both atrial anatomy and endoawicular thrombosis with a clear improvement in patient management both in clinical and economic terms.

NCT ID: NCT06151132 Completed - Clinical trials for Cardiovascular Diseases

Treatment of Atrial Fibrillation in the Community Settings

Start date: January 1, 2016
Phase:
Study type: Observational

Description of treatment of cardiovascular diseases in community settings in Russia

NCT ID: NCT06095791 Completed - Atrial Fibrillation Clinical Trials

Identification of Immunomodulators Associated With Atrial Fibrillation Reporting: Analysis of the WHO Pharmacovigilance Database

Start date: August 1, 2022
Phase:
Study type: Observational

Atrial fibrillation is the most prevalent sustained arrhythmia worldwide with a great morbimortality. Some populations are more at risk to develop atrial fibrillation like patients suffering from inflammatory diseases or patients suffering from cancers. This is at least explained by the inflammatory environment related to these both conditions. Many experimental studies and clinical studies support the role of inflammation and immunity in atrial fibrillation genesis by modulating atrial action potential et by promoting fibrosis. Immunomodulators are drugs used to stimulate or inhibit the immune system for two main indications : cancers and immune disorder diseases which both promote atrial fibrillation. Due to their interactions with inflammation and immunity, immunomodulatores may further promote the risk of atrial fibrillation, particularly in a population already at risk. Based on the World Health Organization global database, the main objective of this study is to investigate the association between immunomodulators and the occurrence of atrial fibrillation reported in the database. A disproportionality analysis will be performed. It will aim to assess whether immunomodulators are associated with a greater risk of atrial fibrillation. Secondary objectives aim to describe the cases of atrial fibrillation among immunomodulators associated with atrial fibrillation in the main analysis, to describe coprescription among immunomodulators associated with atrial fibrillation in the main analysis, to analyse the role of immunomoduloators medical indication in the overrisk of atrial fibrillation, and to try to highlight some immune mechanisms promoting atrial fibrillation regarding the immunomodulators associated with atrial fibrillation in the main analysis.

NCT ID: NCT06028893 Completed - Atrial Fibrillation Clinical Trials

REal-worLd vAlidaTION of PhotoPlehtysmoGraphy (for Atrial Fibrillation Detection)

RELATION PPG
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Mobile health solutions for rhythm monitoring (e.g. atrial fibrillation detection) using photoplethysmography (PPG) technology on a smartphone have been developed. This study validates the performance of a digital health application (FibriCheck®) using PPG technology on a smartphone against a single-lead ECG device (Kardia Mobile®).

NCT ID: NCT06023290 Completed - Atrial Fibrillation Clinical Trials

Validation of Digital Heart Rhythm Devices in the Detection of Atrial Fibrillation

VALIDATION
Start date: July 3, 2023
Phase: N/A
Study type: Interventional

The VALIDATION study aims to evaluate the performance of four state-of-the-art digital heart rhythm devices (Preventicus®, FibriCheck®, Apple Watch®, 6L Kardia Mobile®) for the detection of atrial fibrillation.